Litigation

Recent Posts

7th Circuit Says Motion To Consolidate Depakote Suits Triggers CAFA Jurisdiction
Posted on 17 Oct 2012 by Tom Moylan

CHICAGO - Resolving a split between two district courts, the Seventh Circuit U.S. Court of Appeals on Oct. 16 ruled that plaintiffs' motions to consolidate 10 Illinois state court cases involving Abbott Laboratories' anti-seizure drug Depakote... Read More

William A. Ruskin: Frye Decision In BMW Case Results In Exclusion Of Plaintiff's Experts
Posted on 25 Jan 2013 by William A. Ruskin

By William A. Ruskin In a thoughtful decision handed down in Reeps v. BMW of North America, LLC , 2012 N.Y. Slip Op.33030(u) [ enhanced version available to lexis.com subscribers ], on December 16, 2012 in New York County Supreme Court, the Hon. Louis... Read More

Effort On To Limit 'Public Interest' Proposition 65 Settlement Releases In California
Posted on 10 Feb 2012 by Thomas H. Clarke, Jr.

California's Proposition 65 ( Sections 25249.5 et seq Health & Safety Code ) is an unusual regulatory scheme. Lawsuits may be filed by private individuals. Plaintiffs are not required to have standing. The law only addresses a warning requirement;... Read More

Zoloft Birth Defects MDL Created, Assigned To Eastern District Of Pennsylvania
Posted on 17 Apr 2012 by Tom Moylan

WASHINGTON, D.C. - (Mealey's) More than 92 federal lawsuits alleging birth defects caused by the antidepressant Zoloft and its generic version sertraline were centralized April 17 before Judge Cynthia M. Rufe in the U.S. District Court for the Eastern... Read More

Zoloft® & SSRIs: The Plaintiffs’ Perspective - An HB Law & Science Conference Report
Posted on 22 Aug 2011 by HB Litigation Conferences

Two major classes of drugs recently have been the subject of mass tort litigation for their alleged tendency to cause birth defects. The first group includes Topamax® and Topiramate, used to treat migraines, and the second comprises Zoloft® and... Read More

Glaxo Takes $2.36 Billion Charge On Legal Costs
Posted on 15 Jul 2010 by LexisNexis Litigation Resource Community Staff

LONDON - (AP) Pharmaceutical company GlaxoSmithKline said Thursday it expects to take a $2.36 billion charge against second-quarter earnings for the costs of settling court cases over the antidepressant Paxil and diabetes drug Avandia. The company said... Read More